Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-07-11
2009-10-06
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C514S885000
Reexamination Certificate
active
07597892
ABSTRACT:
Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
REFERENCES:
patent: 5591630 (1997-01-01), Anderson et al.
patent: 5660824 (1997-08-01), Grabstein et al.
patent: 5798966 (1998-08-01), Keeney
patent: 6001973 (1999-12-01), Strom et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6083477 (2000-07-01), Goldenberg
patent: 6114598 (2000-09-01), Kucherlapati et al.
patent: 6165466 (2000-12-01), Grabstein et al.
patent: 6184359 (2001-02-01), Grabstein et al.
patent: 6258352 (2001-07-01), Shimonaka
patent: 6632927 (2003-10-01), Adair et al.
patent: 7247304 (2007-07-01), van de Winkel et al.
patent: 2002/0182178 (2002-12-01), Grooten et al.
patent: 2232813 (1997-04-01), None
patent: 1273304 (2003-01-01), None
patent: 1273304 (2003-01-01), None
patent: 11-500908 (1999-01-01), None
patent: WO-96/34096 (1996-10-01), None
patent: WO-98/37757 (1998-09-01), None
patent: WO-99/45962 (1999-09-01), None
patent: WO-00/02582 (2000-01-01), None
patent: WO-00/02582 (2000-01-01), None
patent: WO-01/02003 (2001-01-01), None
patent: WO-02/22805 (2002-03-01), None
patent: WO-03/017935 (2003-03-01), None
patent: WO-2004/076620 (2004-09-01), None
Casset, Florence et al., “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design,”Biochemical and Biophysical Research Communications, vol. 307:198-205 (2003).
Chen, Yvonne et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen,”J. Mol. Biol., vol. 293:865-881 (1999).
De Pascalis, Roberto et al., “Grafting of ‘Abbreviated’ Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody,”The Journal of Immunology, vol. 169:3076-3084 (2002).
Holm, Patrik et al., “Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1,”Molecular Immunology, vol. 44:1075-1084 (2007).
MacCallum, Robert M. et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography,”J. Mol. Biol., vol. 262:732-745 (1996).
Vajdos, Felix F. et al., “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis,”J. Mol. Biol., vol. 320:415-428 (2002).
Wu, Herren et al., “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues,”J. Mol. Biol., vol. 294:151-162 (1999).
Canadian Office Action for Application No. 2456648, dated Nov. 19, 2007.
Amit, A.G. et al., “Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution,”Science, vol. 233:747-753 (1986).
Bentley, David L., “Most κ immunoglobulin mRNA in human lymphocytes is homologous to a small family of germ-line V genes,”Nature, vol. 307(5946):77-80 (1984).
Davies, Julian et al., “Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding,”Immunotechnology, vol. 2:169-179 (1996).
Kipps, Thomas J. et al., “Autoantibody-Associated κ Light Chain Variable Region Gene Expressed in Chronic Lymphocytic Leukemia with Little or No Somatic Mutation,”J. Exp. Med., vol. 167:840-852 (1988).
Panka, David J. et al., “Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies,”Proc. Natl. Acad Sci. USA, vol. 85:3080-3084 (1988).
Rudikoff, Stuart et al., “Single amino acid substitution altering antigen-binding specificity,”Proc. Natl. Acad. Sci. USA, vol. 79:1979-1983 (1982).
Stausberg, R.L. et al., “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences,”PNAS, vol. 99(26):16899-16903 (2002).
The Merck Manual of Diagnosis and Therapy, 17th Edition, Mark H. Beers and Robert Berkow, Eds., Merck Research Laboratories, pp. 165-177 and pp. 986-995 (1999).
Villadsen, Louise S. et al., “Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model,”The Journal of Clinical Investigation, vol. 112(10):1571-1580 (2003).
Fehniger, Todd A. et al., “Interleukin 15: biology and relevance to human disease,”Blood, vol. 97(1):14-32 (2001).
McInnes, Iain B. et al., “Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis,”Nature Medicine, vol. 3(2):189-195 (1997).
European Search Report for Application No. 02796411.3-2402, dated Jul. 4, 2007.
Pettit, Dean K. et al., “Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling,”The Journal of Biological Chemistry, vol. 272(4):2312-2318 (1997).
Waldmann, Thomas A. et al., “Contrasting Roles of IL-2 and IL-15 in the Life and Death of Lymphocytes: Implications and Immunotherapy,”Immunity, vol. 14:105-110 (2001).
Baadsgaard Ole
Gerritsen Arnout F.
Petersen Jürgen
Schuurman Janine
Van De Winkel Jan G. J.
DiGiorgio Jeanne M.
Genmab A/S
Lahive & Cockfield LLP
Mertz Prema
Remillard Jane E.
LandOfFree
Method for treating psoriasis by administering human... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating psoriasis by administering human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating psoriasis by administering human... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4142775